Swiss National Bank increased its stake in LivaNova PLC (NASDAQ:LIVN) by 2.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 90,619 shares of the company’s stock after acquiring an additional 1,900 shares during the period. Swiss National Bank owned about 0.18% of LivaNova worth $6,521,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the stock. Comerica Bank raised its position in shares of LivaNova by 127.4% during the 2nd quarter. Comerica Bank now owns 72,378 shares of the company’s stock valued at $5,245,000 after purchasing an additional 40,554 shares during the period. Envestnet Asset Management Inc. grew its stake in LivaNova by 4.9% during the second quarter. Envestnet Asset Management Inc. now owns 10,669 shares of the company’s stock valued at $768,000 after acquiring an additional 495 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in LivaNova by 2,237.1% during the second quarter. DekaBank Deutsche Girozentrale now owns 271,100 shares of the company’s stock valued at $19,512,000 after acquiring an additional 259,500 shares in the last quarter. Wedge Capital Management L L P NC purchased a new position in LivaNova during the second quarter valued at $11,937,000. Finally, Stevens Capital Management LP purchased a new position in LivaNova during the second quarter valued at $257,000. Institutional investors own 84.82% of the company’s stock.
LIVN stock opened at $75.22 on Wednesday. LivaNova PLC has a 12 month low of $64.80 and a 12 month high of $131.54. The company has a current ratio of 0.95, a quick ratio of 0.67 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $76.28 and a 200 day moving average price of $79.59. The stock has a market cap of $3.65 billion, a PE ratio of 23.73, a P/E/G ratio of 2.96 and a beta of 0.56.
In other news, CEO Damien Mcdonald sold 1,000 shares of LivaNova stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $73.58, for a total value of $73,580.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Thad Allen Huston sold 2,000 shares of LivaNova stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $81.49, for a total transaction of $162,980.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 7,500 shares of company stock worth $579,535. Insiders own 0.41% of the company’s stock.
Several equities analysts recently weighed in on the stock. Piper Jaffray Companies reaffirmed a “buy” rating on shares of LivaNova in a research note on Wednesday, July 31st. BidaskClub cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Needham & Company LLC set a $91.00 target price on shares of LivaNova and gave the company a “buy” rating in a research note on Wednesday, July 31st. Zacks Investment Research raised shares of LivaNova from a “hold” rating to a “strong-buy” rating and set a $89.00 target price for the company in a research note on Wednesday, August 7th. Finally, BTIG Research reaffirmed a “hold” rating on shares of LivaNova in a research note on Wednesday, July 31st. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. LivaNova currently has a consensus rating of “Buy” and a consensus target price of $104.17.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV?) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Further Reading: Understanding Analyst Recommendations
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.